- Home
- OPBK vs VOR Comparison
OPBK vs VOR Comparison
Compare OPBK & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPBK | VOR |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.0M | 207.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OPBK | VOR |
|---|---|---|
| Price | $14.40 | $12.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $16.50 | ★ $66.63 |
| AVG Volume (30 Days) | 48.2K | ★ 3.8M |
| Earning Date | 01-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 13.19 | N/A |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $87,081,000.00 | N/A |
| Revenue This Year | $22.56 | N/A |
| Revenue Next Year | $9.60 | N/A |
| P/E Ratio | $8.87 | ★ N/A |
| Revenue Growth | ★ 10.57 | N/A |
| 52 Week Low | $10.43 | $2.62 |
| 52 Week High | $16.07 | $65.80 |
Technical Indicators
Market Signals| Indicator | OPBK | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 49.87 |
| Support Level | $13.88 | $10.29 |
| Resistance Level | $14.52 | $13.88 |
| Average True Range (ATR) | 0.34 | 1.55 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 38.13 | 48.19 |
Price Performance
Historical ComparisonAbout OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.